Literature DB >> 10557095

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.

L M Smith1, S C Wise, D T Hendricks, A L Sabichi, T Bos, P Reddy, P H Brown, M J Birrer.   

Abstract

We have previously demonstrated decreased Jun/AP-1 activity in the breast cancer cell line MCF-7 when compared to normal or immortalized mammary epithelial cells. In this paper, we overexpress Jun in MCF-7 cells (MCF7Jun) and demonstrate that it results in diverse biologic and biochemical changes, which mimic those seen clinically in breast cancer. Overexpression of Jun causes significant alterations in the composition of AP-1, decreased junB and increased fra-1 expression and results in an increased biologic aggressiveness. MCF7Jun cells exhibit increased cellular motility, increased expression of a matrix degrading enzyme MMP-9, increased in vitro chemoinvasion and tumor formation in nude mice in the absence of exogenous estrogens. Furthermore, MCF7Jun cells are unresponsive to the growth stimulating effects of estrogen and growth inhibitory effects of tamoxifen. Analysis of the estrogen receptor (ER) expression and activity showed that the MCF7Jun cells have no detectable ER. MCF-7 cells overexpressing mutant forms of cJun were responsive to the growth stimulatory effects of estrogen indicating that full-length cJun is required to acquire the estrogen-independent phenotype in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10557095     DOI: 10.1038/sj.onc.1202989

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  61 in total

1.  COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis.

Authors:  Jing Shao; Yong Teng; Ravi Padia; Sungguan Hong; Hyangsoon Noh; Xiayang Xie; Jeff S Mumm; Zheng Dong; Han-Fei Ding; John Cowell; Jaejik Kim; Jiahuai Han; Shuang Huang
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  Prognostic impact of transcription factor Fra-1 in ER-positive breast cancer: contribution to a metastatic phenotype through modulation of tumor cell adhesive properties.

Authors:  L Oliveira-Ferrer; M Kürschner; V Labitzky; D Wicklein; V Müller; G Lüers; U Schumacher; K Milde-Langosch; C Schröder
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-10       Impact factor: 4.553

3.  Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18.

Authors:  Karen A Gould; Martin Tochacek; Beverly S Schaffer; Tanya M Reindl; Clare R Murrin; Cynthia M Lachel; Eric A VanderWoude; Karen L Pennington; Lisa A Flood; Kimberly K Bynote; Jane L Meza; Michael A Newton; James D Shull
Journal:  Genetics       Date:  2004-12       Impact factor: 4.562

4.  Statistical significance of combinatorial regulations.

Authors:  Aika Terada; Mariko Okada-Hatakeyama; Koji Tsuda; Jun Sese
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-23       Impact factor: 11.205

5.  Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma.

Authors:  Virna D Leaner; Jeffrey F Chick; Howard Donninger; Ilona Linniola; Arnulfo Mendoza; Chand Khanna; Michael J Birrer
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

6.  Chromosomal changes in aggressive breast cancers with basal-like features.

Authors:  Wayne Yu; Yasmine Kanaan; Young Kyung Bae; Young-Kyung Baed; Edward Gabrielson
Journal:  Cancer Genet Cytogenet       Date:  2009-08

7.  Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C.

Authors:  Tobias N Dechow; Laura Pedranzini; Andrea Leitch; Kenneth Leslie; William L Gerald; Irina Linkov; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

8.  c-Jun/AP-1 pathway-mediated cyclin D1 expression participates in low dose arsenite-induced transformation in mouse epidermal JB6 Cl41 cells.

Authors:  Dongyun Zhang; Jingxia Li; Jimin Gao; Chuanshu Huang
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-14       Impact factor: 4.219

9.  BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer.

Authors:  Ali Naderi; Ji Liu; Luke Hughes-Davies
Journal:  Mol Cancer       Date:  2010-05-19       Impact factor: 27.401

10.  JAB1/CSN5: a new player in cell cycle control and cancer.

Authors:  Terry J Shackleford; Francois X Claret
Journal:  Cell Div       Date:  2010-10-18       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.